scholarly journals Prostate-specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer

2017 ◽  
Vol 120 (3) ◽  
pp. 310-312 ◽  
Author(s):  
John A. Violet ◽  
Michael S. Hofman
Keyword(s):  
Prostate Cancer ◽  
Therapeutic Target ◽  
Radionuclide Therapy ◽  
Prostate Specific Membrane Antigen ◽  
Specific Membrane ◽  
Target Radionuclide Therapy

Is prostate-specific membrane antigen a multifunctional protein?

2005 ◽  
Vol 288 (5) ◽  
pp. C975-C981 ◽  
Author(s):  
Ayyappan K. Rajasekaran ◽  
Gopalakrishnapillai Anilkumar ◽  
Jason J. Christiansen
Keyword(s):  
Prostate Cancer ◽  
Signal Transduction ◽  
Epithelial Cells ◽  
Therapeutic Target ◽  
Clinical Utility ◽  
Biological Function ◽  
Prostate Specific Membrane Antigen ◽  
Multifunctional Protein ◽  
Prostate Epithelial Cells ◽  
Specific Membrane

Prostate-specific membrane antigen (PSMA) is a metallopeptidase expressed predominantly in prostate cancer (PCa) cells. PSMA is considered a biomarker for PCa and is under intense investigation for use as an imaging and therapeutic target. Although the clinical utility of PSMA in the detection and treatment of PCa is evident and is being pursued, very little is known about its basic biological function in PCa cells. The purpose of this review is to highlight the possibility that PSMA might be a multifunctional protein. We suggest that PSMA may function as a receptor internalizing a putative ligand, an enzyme playing a role in nutrient uptake, and a peptidase involved in signal transduction in prostate epithelial cells. Insights into the possible functions of PSMA should improve the diagnostic and therapeutic values of this clinically important molecule.

Dual Contrast Agents for Fluorescence and Photoacoustic Imaging: Evaluation in a Murine Model of Prostate Cancer

Nanoscale ◽  
2021 ◽  
Author(s):  
Wojtek Lesniak ◽  
Yixuan Yu ◽  
Jeeun Kang ◽  
Srikanth Boinapally ◽  
Sangeeta Ray Banerjee ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Drug Delivery ◽  
Contrast Agents ◽  
Murine Model ◽  
Therapeutic Target ◽  
Photoacoustic Imaging ◽  
Pamam Dendrimers ◽  
Prostate Specific Membrane Antigen ◽  
Imaging Evaluation ◽  
Specific Membrane

Prostate-specific membrane antigen (PSMA) is a promising diagnostic and therapeutic target for prostate cancer (PC). Poly(amidoamine) [PAMAM] dendrimers serve as versatile scaffolds for imaging agents and drug delivery that can...

479: Prostate-Specific Membrane Antigen (PSMA) Expression as a Predictor of Prostate Cancer Progression

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-156
Author(s):  
Matthias D. Hofer ◽  
Sven Perner ◽  
Haojie Li ◽  
Rainer Kuefer ◽  
Richard E. Hautmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Progression ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cancer Progression ◽  
Specific Membrane ◽  
Psma Expression

scholarly journals Spotlight on PSMA as a new theranostic biomarker for bladder cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Maria Maddalena Tumedei ◽  
Sara Ravaioli ◽  
Federica Matteucci ◽  
Monica Celli ◽  
Ugo De Giorgi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Diagnostic Tests ◽  
Radionuclide Therapy ◽  
Tumor Type ◽  
Prostate Specific Membrane Antigen ◽  
Bladder Tissue ◽  
Tissue Samples ◽  
Specific Membrane ◽  
Psma Expression ◽  
Degree Of Extension

AbstractBladder cancer (BCa) patients are diagnosed by cytology and cystoscopy. However, these diagnostic tests bear some limitations. We sought for reliable biomarkers to better determine BCa extension. Prostate-specific membrane antigen (PSMA) appears to fulfill this requirement in prostate cancer but its role in BCa has not been established yet. We then analyzed 87 bladder tissue samples from 74 patients assessing PSMA expression by immunohistochemistry. The median PSMA expression, exclusively found in tumor neovasculature, in terms of H-score significantly differed between non-tumor samples and tumor samples (p = 0.00288) showing a higher neovasculature-related PSMA expression. No differences were observed in relation to tumor type, grade and stage. BCa neovasculature-related PSMA overexpression may be useful in defining the degree of extension of the neoplasm. In addition, testing PSMA expression by immunohistochemistry may hold theranostic implications both considering anti-angiogenesis agents and radio-labelled PSMA ligands for intracavitary radionuclide therapy. In our opinion, BCa neovasculature-related PSMA overexpression may be considered an apt target for anti-angiogenesis and radionuclide treatment in BCa, once the evaluation of tumor-retention time for the appropriateness of long half-life therapeutic PSMA ligands as radionuclide treatment will be performed.

scholarly journals 225Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient

2021 ◽  
Vol 10 (5) ◽  
pp. 205846012110225
Author(s):  
Omer Aras ◽  
Stefan Harmsen ◽  
Richard Ting ◽  
Haluk B Sayman
Keyword(s):  
Prostate Cancer ◽  
Standard Of Care ◽  
Complete Response ◽  
Prostate Specific Membrane Antigen ◽  
Limited Data ◽  
Castrate Resistant Prostate Cancer ◽  
Targeting Peptide ◽  
Castrate Resistant ◽  
Specific Membrane

Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to 225Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive 177Lu-PSMA-617. In addition, the patient’s baseline germline mutation likely predisposed him to more aggressive disease.

Sign in / Sign up

Export Citation Format

Share Document